Glenmark Pharmaceuticals has reported results for third quarter ended December 31, 2013.
The company has reported 46.44% fall in its net profit at Rs 58.40 crore for the quarter as compared to Rs 109.03 crore for the same quarter in the previous year. Total income from operations of the company decreased by 2.30% at Rs 543.16 crore for quarter under review, as compared to Rs 555.94 crore for the quarter ended December 31, 2012.
On the consolidated basis, the group has reported modest 1.56% rise in its net profit at Rs 216.23 crore for the quarter as compared to Rs 212.91 crore for the same quarter in the previous year. Total income from operations of the company has increased by 15.87% at Rs 1606.83 crore for quarter under review as compared to Rs 1386.76 crore for the quarter ended December 31, 2012.
The company has reported 46.44% fall in its net profit at Rs 58.40 crore for the quarter as compared to Rs 109.03 crore for the same quarter in the previous year. Total income from operations of the company decreased by 2.30% at Rs 543.16 crore for quarter under review, as compared to Rs 555.94 crore for the quarter ended December 31, 2012.
On the consolidated basis, the group has reported modest 1.56% rise in its net profit at Rs 216.23 crore for the quarter as compared to Rs 212.91 crore for the same quarter in the previous year. Total income from operations of the company has increased by 15.87% at Rs 1606.83 crore for quarter under review as compared to Rs 1386.76 crore for the quarter ended December 31, 2012.
No comments:
Post a Comment